Capivasertib (Truqap®). HTA ID: 24015

Assessment Status Rapid Review Complete
HTA ID 24015
Drug Capivasertib
Brand Truqap®
Indication Capivasertib (Truqap®) is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.
Assessment Process
Rapid review commissioned 30/04/2024
Rapid review completed 29/05/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of capivasertib in combination with fulvestrant compared with the current standard of care.